Background
==========

Exploiting the immune system's ability to identify and destroy tumours using immunotherapy has long been recognised as a promising approach to anticancer treatment \[[@B1]\]. However, traditional immunotherapies such as interferon and interleukin-2 have generally failed to demonstrate consistent clinical benefit in advanced stage cancer.

The recent renaissance of cancer immunotherapy can be largely attributed to the development of novel immunotherapy agents which target specific immune regulatory checkpoints to enhance the endogenous antitumour immune response. After becoming the first agent to demonstrate a significant overall survival (OS) improvement in a randomised phase 3 trial in metastatic melanoma \[[@B2]\], the anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab was approved for this indication (although, in Europe, its initial indication was restricted to patients who had received prior therapy) \[[@B3]\]. In the last 3 years, we have gained a wealth of experience with this and other immunotherapies in the clinical setting and learned a considerable amount regarding their potential benefit across multiple tumour types.

CTLA-4 is a key inhibitory checkpoint molecule that is thought to counteract the co-stimulatory signal from its homologue, CD28, by competitively binding to its ligands (B7.1 and B7.2) on the surface of antigen-presenting cells \[[@B4]\]. Tumour cells exploit this pathway to turn off the immune response by suppressing the activation and proliferation of conventional T cells and promoting the function of regulatory T cells (Tregs) which can dampen the immune response at the tumour site \[[@B5],[@B6]\]. By blocking CTLA-4, ipilimumab restores the co-stimulatory activity of CD28, thereby increasing the number of activated T cells that can migrate to and attack the tumour \[[@B7]\]. Recent data have also demonstrated that treatment with CTLA-4 antibodies can mediate selective depletion of Treg cells within the tumour \[[@B8]\].

In addition to CTLA-4, numerous other immune checkpoints exist that are potential targets for immunotherapy \[[@B9],[@B10]\]. For example, interaction of the programmed death 1 (PD1) receptor with its ligands (PDL1 and PDL2) in peripheral sites leads to T-cell inactivation and loss of effector function. Targeting this pathway using antibodies against PD1 (e.g. nivolumab, pembrolizumab) or PDL1/PDL2 (e.g. MPDL3280A, MEDI4736) breaks down this mechanism, preventing T-cell inactivation and restoring immune activity directly at the tumour site \[[@B11]\]. Immunotherapies targeting other immune checkpoint molecules such as LAG3 and CD137 (4-1-BB) are also under evaluation in advanced malignancies, either as monotherapy or in combination with other therapies (Figure [1](#F1){ref-type="fig"}).

![**Immuno-oncology agents**^**a**^**in clinical development across multiple tumour types.**^a^Selected therapies and tumour types are shown: additional agents are, for example in phase 1 studies in patients with solid tumours \[[@B12]\]. AML, acute myeloid leukemia; CLL, chronic lymphocytic leukaemia; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; CTLA-4, cytotoxic T-lymphocyte antigen-4; GIST, gastrointestinal stromal tumour; HCC, hepatic cell carcinoma; LAG-3, lymphocyte activation gene 3; mAb, monoclonal antibody; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PC, prostate cancer; PD1, programmed death 1; RCC, renal cell carcinoma; SCLC, small cell lung cancer.](1479-5876-12-141-1){#F1}

Adoptive T cell therapy (ATC) using chimeric antigen receptors (CARs) is an alternative immunotherapeutic approach to anticancer therapy. This approach combines the antigen-binding property of monoclonal antibodies with the lytic capacity and self-renewal of T cells \[[@B13]\]. Clinical trials have revealed promising results in patients with CD19-positive haematological malignancies, including non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and acute lymphoblastic leukaemia; further trials in patients with B-cell malignancies or solid tumours are ongoing \[[@B13]\].

ATC therapy using autologous *ex vivo-*expanded tumour infiltrating lymphocytes (TILs) that are then adoptively transferred back into patients is an immunotherapy that has shown clinical efficacy in metastatic melanoma \[[@B14]\]. In one study, the immunodominant epitope recognised by the tumour-reactive T-cells was identified as a mutated protein phosphatase 1, regulatory (inhibitor) subunit 3B (PPP1R3B) gene product; the patient achieved a durable complete response with regression of bulky liver tumour mass \[[@B15]\].

Efforts to determine an effective vaccine that alerts the immune system to cancer cells have largely failed; however, experimental cancer vaccines containing proteins that are overexpressed by tumour cells may work synergistically with other immunotherapies \[[@B16],[@B17]\]. Talimogene laherparepvec (T-VEC) is a genetically modified virus which drives the secretion of the immunostimulatory cytokine granulocyte macrophage colony stimulating factor (GM-CSF) \[[@B18]\]. T-VEC is currently being evaluated as a potential treatment in melanoma and other advanced cancers \[[@B19],[@B20]\]. In a pre-clinical study in breast cancer bearing mice, the combination of an anti-PD1 antibody and a multi-peptide vaccine prolonged the vaccine-induced progression-free survival (PFS) by altering both the CD8 T-cell and dendritic cell components of the tumour microenvironment \[[@B21]\].

Currently, the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) tumor-node-metastasis (TNM) classification provides limited prognostic information and does not predict response to therapy. However, it is now becoming clear that the host-immune reaction to tumours is a critical element in determining response to therapy. This has led to the development of an 'Immunoscore' which correlates immune-cell infiltration in tumors to patient's clinical outcome. Recent work has reported that such an immune-classification has a prognostic value that may be superior to the AJCC/UICC TNM-classification, and studies are ongoing to validate and integrate such a system into clinical practice \[[@B22]\].

Responses to immunotherapy may be delayed or may develop after a period of apparent disease progression due to the time required to build an effective immune response; therefore, tumour assessments should be performed only after completion of the assigned regimen and the results confirmed with a follow-up scan \[[@B23]\]. For ipilimumab, the recommended induction regimen is 3 mg/kg, administered every 3 weeks for 4 doses; this is sufficient to provide a considerable survival benefit in a proportion of patients \[[@B2],[@B3]\]. To maximise clinical benefit, it is also recommended that ipilimumab is administered for the entire induction regimen as tolerated, regardless of the appearance of new lesions or growth of existing lesions, as immune cell infiltration following immunotherapy may be mistaken for tumour progression \[[@B24]\]. In addition, the unconventional nature of some responses with ipilimumab have made it necessary to introduce new criteria to characterise antitumour activity, as conventional assessment methods may not fully capture these novel response patterns. Immune-related response criteria (irRC) were developed from existing modified World Health Organisation (mWHO) criteria; the irRC allow for initial tumour progression or appearence of new lesions, both of which would be considered as progressive disease according to mWHO criteria \[[@B23]\]. Although irRC were developed based on response patterns observed with ipilimumab, the possibility of unconventional, immune-related response patterns must be also considered for other immunotherapies, including nivolumab and other anti-PD1/PDL1 agents. Indeed, responses with nivolumab may be rapid or delayed, and may continue after therapy is discontinued \[[@B25]\].

An emerging understanding of the biology affecting the results of immunotherapy leads to the conclusion that surrogate endpoints such as objective response rates and PFS may not be appropriate for measuring long-term treatment benefit \[[@B26]\]. Data from clinical trials and ipilimumab expanded access programmes (EAPs) indicate that long-lasting stable disease is a common outcome with immunotherapy and that, even in the absence of a complete or partial tumour response, durable disease control can result in prolonged OS \[[@B23],[@B27]\]. Efficacy endpoints that better correlate with prolonged survival, such as landmark survival analyses are therefore becoming more relevant since they take into consideration the durability of survival \[[@B26]\].

Kaplan-Meier curves of OS in patients treated with ipilimumab show that survival consistently reaches a plateau at around 2--3 years \[[@B2],[@B28]-[@B31]\], as demonstrated in both randomised phase 3 trials of ipilimumab in metastatic melanoma (Figure [2](#F2){ref-type="fig"}). Beyond this time point, the long 'tail' of the survival curve reflects the emergence of long-term survivors and highlights the importance of using landmark survival analyses as well as hazard ratios and median OS, to benchmark survival outcomes. In a phase 3 trial investigating survival with ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC), the 2-year survival rate with ipilimumab was 26%, compared with 15% for patients in the placebo arm \[[@B32]\]. Furthermore, in a recent meta-analysis of 1,861 patients with metastatic melanoma who received ipilimumab in phase 2 and phase 3 trials, the 3-year survival rate was 22% and around one fifth of patients survived for up to 10 years, irrespective of prior treatment \[[@B33]\]. Notably, inclusion of EAP data did not affect the overall shape of the pooled survival curve, indicating that the potential for long-term survival persists even in patients with a particularly poor prognosis. In both the meta-analysis and the prostate cancer trial, the shape of the OS curves for ipilimumab-treated patients appeared remarkably similar to those seen in the pivotal phase 3 trials in melanoma. Additional data from clinical trials suggest that targeting other immune checkpoints can provide long-term survival benefits. For example, in a phase 1 clinical trial evaluating nivolumab in patients with advanced solid tumours, the 2-year survival rates were 14% in non-small cell lung cancer (NSCLC), 43% in melanoma, and 50% in renal cell carcinoma (RCC) \[[@B34],[@B35]\]. At present, no median OS or long-term survival data are available for pembrolizumab; however, rapid and durable tumour regressions have been observed with this agent as well as with nivolumab. Indeed, durable objective responses may be considered a key endpoint in the future as we enter a new era of immunotherapy requiring more stringent evaluation \[[@B36]\]. With regard to other immunotherapies, in an interim survival analysis from a phase 3 trial of T-VEC versus GM-CSF in patients with advanced melanoma, the 3-year survival rates were 41% and 28% for patients treated with T-VEC and GM-CSF, respectively \[[@B19],[@B20]\]. These results are extremely encouraging for patients with advanced malignancies and have fuelled speculation that the availability of novel immunotherapies could potentially result in cancer turning into a controllable chronic disease in a considerable proportion of patients.

![**Kaplan-Meier curves of OS in patients treated with ipilimumab.** OS curves from two randomised phase 3 trials of ipilimumab in patients with metastatic melanoma: **A)** MDX010-20 trial, and **B)** CA184-024 trial.](1479-5876-12-141-2){#F2}

Evidence suggests that a number of immuno-oncology approaches do not require identification of specific tumour antigens and thus provide the potential to offer clinical benefit across many different types of cancer. Based on this rationale, monoclonal antibodies targeting a variety of immune checkpoints inhibitors (e.g. anti-CTLA-4, anti-PD1, and anti-LAG3) have been investigated across multiple tumour types, including prostate cancer, lung cancer and RCC \[[@B32],[@B34],[@B37]-[@B42]\]. For example, in a phase 3 trial in patients with mCRPC, ipilimumab treatment improved PFS and prostate specific antigen (PSA) responses versus placebo when administered after a single dose of radiotherapy (RT). Although the primary endpoint of improved OS was not met (the hazard ratio for OS versus placebo was 0.85; *P* = 0.05), the results of an OS subgroup analysis suggested that patients with a lower disease burden may be more likely to benefit from ipilimumab treatment \[[@B32]\]; an ongoing phase 3 trial of ipilimumab in patients with chemotherapy-naïve mCRPC is prospectively evaluating this patient population.

Encouraging results have also been observed in ipilimumab clinical trials in patients with advanced lung cancer. In a phase 2 trial, there was a trend towards improved survival in patients who received ipilimumab 10 mg/kg after carboplatin and paclitaxel (CP) compared with CP alone \[[@B38],[@B39]\]; two randomised phase 3 trials to evaluate ipilimumab in NSCLC (NCT01285609) or SCLC (NCT01450761) are open for enrollment.

Among other investigational immunotherapies, the anti-PD1 antibody nivolumab has been evaluated in a variety of tumour types. In the phase 1 trial described earlier, median OS was 9.6 months, 16.8 months and \>22 months, in patients with NSCLC, melanoma and RCC, respectively \[[@B34],[@B35]\]; phase 3 trials of nivolumab in each of these indications are currently ongoing. Other immune checkpoint inhibitors, including other anti-PD1/PDL1 agents, anti-LAG3 antibodies and anti-KIR antibodies, are also under evaluation in various solid tumours and haematological malignancies.

As immunotherapy works to enhance the host's own immune system rather that acting directly on the tumour itself, immuno-oncology approaches have the potential to be effective across patient subpopulations, regardless of mutational status (e.g. BRAF/NRAS) or histological subtype. In melanoma, BRAF inhibitors (vemurafenib and dabrafenib) can provide rapid responses in the 40--50% of patients with a mutation in BRAF V600; however, their use is contra-indicated in patients with wild-type BRAF status \[[@B43]-[@B45]\]. By contrast, BRAF or NRAS mutation status does not appear to be associated with the clinical activity of ipilimumab (Table [1](#T1){ref-type="table"}). In a retrospective multicentre analysis, there was no difference in median OS between patients with BRAF/NRAS-mutated or wild-type melanoma (10.12 months versus 10.18 months) treated with anti-CTLA-4 antibodies \[[@B46]\]. Similarly, disease control rates and survival were comparable between BRAF/NRAS mutant and wild-type patients in the Italian EAP; safety results were consistent across all groups with respect to mutational status \[[@B47]\].

###### 

Clinical trial and real-world data on the use of ipilimumab in patient subpopulations

  **Patient subgroup**         **Efficacy summary**                                                                                                                                                               **Safety summary**                                                            **References**
  ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------
  Elderly patients             *Italian EAP ( \>70 years)*                                                                                                                                                                                                                                       
                               DCR: 38%                                                                                                                                                                           Generally well tolerated; consistent with wider EAP                           Chiarion Sileni et al., 2014 \[[@B48]\]
                               1- year OS: 38%                                                                                                                                                                                                                                                   
                               2-year OS: 22%                                                                                                                                                                     population                                                                     
                               *Spanish EAP (≥65 years)*                                                                                                                                                                                                                                         
                               DCR: 35%                                                                                                                                                                           No increase in toxicity in elderly patients                                   Lopez Martin et al., 2012 \[[@B49]\]
                               1- year OS: 21%                                                                                                                                                                                                                                                   
                               *US EAP (≥65 years)*                                                                                                                                                               Consistent with wider EAP population                                          Lawrence et al., 2012 \[[@B50],[@B51]\]
                               1- year OS: 37%                                                                                                                                                                                                                                                   
                               *NYU retrospective analysis*                                                                                                                                                                                                                                     Chandra et al., 2013 \[[@B52]\]
                               *(≥65 years)*                                                                                                                                                                      Consistent with published data in younger cohorts                              
                               DCR: 36%                                                                                                                                                                                                                                                          
  Uveal melanoma               *Italian EAP*                                                                                                                                                                                                                                                     
                               DCR: 34%                                                                                                                                                                           Safety profile similar to that in cutaneous melanoma                          Maio et al., 2013 \[[@B53]\]
                               1- year OS: 31%                                                                                                                                                                                                                                                   
                               *I-OMEAP (10 mg/kg)*                                                                                                                                                               Consistent with ipilimumab clinical trials                                    Danielli et al., 2012 \[[@B54]\]
                               DCR: 23%                                                                                                                                                                                                                                                          
                               *Royal Marsden*                                                                                                                                                                    Consistent with ipilimumab clinical trials                                    Khattak et al., 2013 \[[@B55]\]
                               DCR: 20%                                                                                                                                                                                                                                                          
                               *US EAP* 1- year OS: 34%                                                                                                                                                           Consistent with wider EAP population                                          Lawrence et al., 2012 \[[@B50],[@B51]\]
                               *Multicentre retrospective analysis*                                                                                                                                                                                                                             Luke et al., 2013 \[[@B56]\]
                               DCR: 46%                                                                                                                                                                           Consistent with ipilimumab clinical trials                                     
  Mucosal melanoma             *Italian EAP*                                                                                                                                                                                                                                                     
                               DCR: 36%                                                                                                                                                                           Safety profile similar to that in cutaneous melanoma                          Del Vecchio et al., 2013 \[[@B57]\]
                               1- year OS: 35%                                                                                                                                                                                                                                                   
                               *US EAP* 1- year OS: 32%                                                                                                                                                           Consistent with wider EAP population                                          Lawrence et al., 2012 \[[@B50],[@B51]\]
                               Multicentre experience                                                                                                                                                                                                                                           Postow et al., 2013 \[[@B58]\]
                               DCR: 27%                                                                                                                                                                           Consistent with ipilimumab clinical trials                                     
  Brain metastases             *CA184-042 phase 2 trial (asymptomatic)*                                                                                                                                                                                                                          
                               DCR: 25%                                                                                                                                                                           Safety results consistent with those previously reported in clinical trials   Margolin et al., 2012 \[[@B59]\]
                               1- year OS: 36%                                                                                                                                                                                                                                                   
                               2-year OS: 21%                                                                                                                                                                                                                                                    
                               *NIBIT-M1 phase 2 trial (+fotemustine; asymptomatic)*                                                                                                                                                                                                             
                                                                                                                                                                                                                  DCR: 50%                                                                       
                                                                                                                                                                                                                  1- year OS: 55%                                                               AEs generally manageable and reversible
                                                                                                                                                                                                                  2-year OS: 39%                                                                 
                               *Italian EAP* DCR: 27%                                                                                                                                                             Safety results consistent with those previously reported in clinical trials   Queirolo et al., 2014 \[[@B62]\]
                               1- year OS: 20%                                                                                                                                                                                                                                                   
                               *US EAP* 1- year OS: 25%                                                                                                                                                           Consistent with wider EAP population                                          Lawrence et al., 2012 \[[@B50],[@B51]\]
  BRAF/NRAS-mutated melanoma   *Phase 2 study CA184-004*                                                                                                                                                                                                                                         
                               (BRAF mutated vs BRAF wild-type)                                                                                                                                                                                                                                 Shahabi et al., 2012 \[[@B63]\]
                               DCR: 30% vs 35%                                                                                                                                                                                                                                                   
                               *NIBIT-M1 phase 2 trial*                                                                                                                                                                                                                                          
                               *(+fotemustine; asymptomatic)*                                                                                                                                                                                                                                   Di Giacomo et al., 2013 \[[@B61]\]
                               (BRAF mutated vs BRAF wild-type)                                                                                                                                                                                                                                  
                               DCR: 60% vs 46%                                                                                                                                                                                                                                                   
                               *Italian EAP*                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                  (BRAF mutated vs BRAF wild-type)                                              Consistent regardless of BRAF and NRAS mutation status
                               DCR: 38% vs 39%                                                                                                                                                                                                                                                   
                               1-year OS: 48% vs 39%                                                                                                                                                                                                                                             
                               (NRAS mutated vs NRAS wild-type)                                                                                                                                                                                                                                  
                               DCR: 57% vs 49%                                                                                                                                                                                                                                                   
                               1-year OS: 43% vs 40%                                                                                                                                                                                                                                             
                               *4 institution retrospective analysis*                                                                                                                                                                                                                            
                               *(ipiliumab or tremelimumab)*                                                                                                                                                                                                                                     
                               Similar median OS between patients with BRAF/NRAS-mutated and BRAF/NRAS wild-type melanoma; trend towards improved OS in wild-type population without prior BRAFi/MEKi treatment                                                                                 Mangana et al., 2013 \[[@B46]\]

AEs, adverse events; BRAFi, BRAF inhibitor; DCR, disease control rate; EAP, expanded access programme; I-OMEAP, ipilimumab-ocular melanoma expanded access program; MEKi, MEK inhibitor; NYU, New York University; OS, overall survival.

BRAF mutations are uncommon in patients with noncutaneous (uveal or mucosal) melanomas \[[@B64]\]; therefore, BRAF inhibitors may have limited utility in these patient populations. Although clinical trial data regarding the use of novel therapies in patients with noncutaneous melanoma are limited, data from EAPs suggest ipilimumab has a similar efficacy and safety profile in patients with advanced uveal or mucosal melanoma to that observed in cutaneous melanoma \[[@B50],[@B51],[@B53]-[@B55],[@B57]\]. In EAP in Italy, the 1-year OS rates in patients with uveal or mucosal melanoma were 31% and 35%, respectively; these values are similar to those reported in the US EAP (34% and 32%, respectively) \[[@B50],[@B53],[@B57]\].

Subgroup analyses from the registrational phase 3 trial (MDX010-20) also suggest ipilimumab provides a consistent survival benefit across patient populations, including those with a historically poor prognosis (e.g. elevated lactate dehydrogenase or poor performance status) \[[@B2],[@B65]\]. In addition, ipilimumab has demonstrated activity in elderly patients and patients with stable asymptomatic brain metastases, providing further support for the potential benefit with immunotherapy in a broad patient population \[[@B50],[@B52],[@B58],[@B60],[@B62]\]. With respect to the clinical activity of other immuno-oncology agents, in a phase 1 trial in patients with advanced solid tumours, objective response rates with nivolumab in NSCLC were similar across different patient groups and histology types \[[@B66]\].

Based on their mechanisms of action and available clinical data, immunotherapy agents may provide greatest clinical benefit if used as early as possible in the treatment paradigm when patients have a better prognosis. Furthermore, patients who eventually undergo disease progression after immunotherapy may have prolonged survival, which may allow the opportunity to receive and potentially benefit from subsequent lines of therapy. In MDX010-20, ipilimumab, with or without gp100, significantly improved median OS compared with gp100 alone despite similar estimates of median progression-free survival among the three treatment arms \[[@B2]\]. This may suggest that, even in some patients without an objective response or stable disease, immunotherapy can prolong survival by slowing the rate of disease progression.

Unlike targeted agents, immuno-oncology agents do not alter the nature of tumour cells, which could otherwise select for rapid disease kinetics. Therefore, initial treatment with immunotherapy does not compromise the ability of patients to respond to subsequent therapy with a BRAF inhibitor. Conversely, around 40% of patients with advanced melanoma who progress after BRAF inhibitor treatment undergo rapid disease progression and thus are unable to complete ipilimumab therapy. In a retrospective analysis of 34 patients with BRAF-mutated melanoma, among 28 patients who received a BRAF inhibitor followed by ipilimumab, 12 patients (43%) had rapid disease progression and were not able to complete ipilimumab treatment. Median OS for patients with rapid progression was 5.7 months, compared with 18.6 months for patients who were able to complete ipilimumab treatment. By comparison, none of the six patients who received ipilimumab followed by a BRAF inhibitor had rapid disease progression and all had disease control after subsequent treatment with a BRAF inhibitor \[[@B67]\]. Similar results were observed in the Italian EAP, whereby median OS was 9.9 and 14.5 months, respectively, for patients who received a BRAF inhibitor before or after ipilimumab treatment. Among 45 patients who received a BRAF inhibitor first, median OS from the end of BRAF inhibitor treatment was significantly longer in patients who were able to complete ipilimumab treatment compared with those who had rapid progression and were unable to complete ipilimumab therapy (12.7 versus 1.2 months; *P* \< 0.001). With regard to optimal treatment sequencing, using immunotherapy first followed by targeted therapy in patients with more indolent disease may therefore offer the best chance of long-term survival \[[@B67]-[@B71]\].

Prior exposure to ipilimumab does not appear to affect outcomes to subsequent anti-PD1 antibody therapy. For example, in a phase 1 expansion study in 135 patients with advanced melanoma who received pembrolizumab, efficacy and safety in 48 patients who had received prior treatment with ipilimumab was similar to that observed in the 87 patients who were ipilimumab treatment-naïve \[[@B36]\].

Although typically used only as palliative therapy or in patients with CNS metastases, there is some evidence to suggest that administering RT after iplimumab may provide additional clinical benefit. For example, in a retrospective analysis of 21 patients who received locoregional RT after progressing on ipilimumab, 11 patients (52%) showed evidence of a systemic objective response or prolonged stable disease outside of the irradiated area \[[@B72]\]. This so-called 'abscopal effect' has also been observed in isolated patient cases when RT has been administered either before or after ipilimumab therapy, suggesting that RT and ipilimumab have potentially synergistic effects on antitumour immunity \[[@B73],[@B74]\].

Ongoing research in oncology focuses on enhancing the proportion of patients who benefit from treatment with immunotherapy. As already eluded to, combining immunotherapies with other treatment modalities such as radiotherapy, chemotherapy or targeted agents could potentially lead to enhanced efficacy as these treatments may have immune-stimulatory properties. Increasing preclinical and clinical evidence suggests that these treatments may have additive effects when administered in combination with immunotherapy \[[@B60],[@B73]-[@B76]\].

Given the numerous immune checkpoints that exist, combining immuno-oncology agents that target different checkpoint pathways is also an attractive therapeutic approach. Tumours exploit these pathways to turn off the immune response in different ways, either by decreasing T-cell proliferation or inactivating T cells at the tumour site \[[@B77]\]. For example, by inhibiting CTLA-4, ipilimumab promotes T-cell proliferation, increasing the number of activated T cells that can migrate to attack the tumour; conversely, anti-PD1 agents such as nivolumab counteract tumour defences specifically within the tumour microenvironment, reactivating T-cell activity and inducing tumour cell death \[[@B9],[@B11]\]. The complementary roles of these two pathways in regulating adaptive immunity are supported by preclinical models in which simultaneous administration of anti-CTLA-4 and anti-PD1 antibodies resulted in enhanced antitumour activity compared with single agent treatments \[[@B78],[@B79]\]. In a phase 1 combination study of ipilimumab and nivolumab in patients with advanced melanoma, 40% of patients treated with the concurrent combination regimen had objective responses and the 1-year OS rate was 82%; notably, responses with the combination were both rapid and deep \[[@B80],[@B81]\]. This combination is being further evaluated versus ipilimumab or nivolumab monotherapy in a phase 3, randomised trial. Accumulating preclinical and clinical data also support the use of other investigational immunotherapy combinations such as nivolumab plus anti-LAG3 and ipilimumab plus GM-CSF \[[@B82],[@B83]\].

Finally, biomarker discovery efforts may help to identify patients who are most likely to benefit from treatment with immunotherapy; immunological markers measured during treatment could also be useful as surrogate markers of clinical response. However, identification of immunotherapy biomarkers is challenging due to the complexity of interactions between the immune system and tumour cells, as well as difficulties in performing standardised immunological assays \[[@B84]\]. At present, no predictive biomarkers have been validated that can be used to guide patient selection for treatment with immunotherapy. Although there are some data to suggest that objective response rates with nivolumab, either as monotherapy or in combination with ipilimumab, are highest in patients with positive PDL1 expression in NSCLC and melanoma, the absence of this marker is not an indication that patients will fail to respond to treatment \[[@B85],[@B86]\].

Given that immunotherapy appears to be effective in a broad patient population, the use of biomarkers to guide treatment selection may not be as relevant for immunotherapies as it is for targeted agents such as BRAF or MEK inhibitors. However, despite the lack of any definitive predictive biomarkers, several immunological parameters have been identified that may serve as early markers of response. For example, increases in absolute lymphocyte count and in the number of circulating T cells that express inducible T-cell costimulator during ipilimumab induction therapy have been found to be associated with higher response rates and/or improved survival outcomes \[[@B27],[@B87]-[@B89]\]. Further prospective, controlled studies are needed to determine whether changes in these markers can be used to predict treatment effects.

Conclusion
==========

Over recent years, immunotherapy has increasingly been acknowledged as the fourth pillar of treatment in advanced cancer alongside surgery, radiotherapy, and chemotherapy, with ipilimumab in advanced melanoma serving as the model for proof of concept. Since the approval of ipilimumab in 2011, a number of post-approval issues of importance to practitioners have arisen, many of which are related to the mechanism of action of immuno-oncology agents. Among these is the potential for immunotherapy to show clinical activity in all subpopulations regardless of tumour genotype or histological subtype. Immunotherapy approaches may also allow the opportunity to slow disease progression and prolong survival even in patients with progressive disease. Another related issue which concerns clinicians is how to optimise the sequencing of treatment with ipilimumab and BRAF inhibitors, with increasing evidence to suggest that clinical benefit may be optimised by administering immunotherapy agents as early as possible in the treatment paradigm. In conclusion, immunotherapy agents may represent the future standards of care for various solid tumours or haematological malignancies, with the potential for providing a meaningful survival benefit. Various strategies combining immune checkpoint regulators with other complementary immunotherapies or different treatment modalities are under investigation to maximise treatment outcomes.
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